Posterior subtenon injection of triamcinolone acetonide reduces the use of intravitreal bevacizumab for diffuse diabetic macular edema - Combination therapy for DDME

Subtenon triamcinolone acetonide (STTA)-treated eyes, as compared to their controls, had significantly more regression of foveal thickness (FT) and improvement of visual acuity (VA) at several time points during the study. The required number of intravitreal injection of bevcizumab (IVB) injections in STTA-treated eyes during the study was 5.00 plus-minus 1.75, which was significantly less than 7.95 plus-minus 1.57 in the control eyes.